37.50
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $83.00 at Morgan Stanley - Defense World
Legend Biotech (NASDAQ:LEGN) Receives Outperform Rating from Royal Bank Of Canada - Defense World
Legend Biotech stock price target raised to $77 by RBC Capital - Investing.com South Africa
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth - Investing.com
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth By Investing.com - Investing.com South Africa
Legend Biotech Q2 2025 slides: CARVYKTI sales surge 136%, adjusted profit achieved - Investing.com
XTX Topco Ltd Takes $307,000 Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
Legend Biotech on Track for Record Losing Streak — Data Talk - Morningstar
Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings - Defense World
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential By Investing.com - Investing.com South Africa
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential - Investing.com India
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Barchart.com
Oracle and GameStop Headline Market Cap Stock Movers on Thursday By Investing.com - Investing.com South Africa
Eli Lilly, General Electric among Tuesday’s market cap stock movers By Investing.com - Investing.com India
Eli Lilly, General Electric among Tuesday’s market cap stock movers - Investing.com
CARVYKTI shows lasting impact in multiple myeloma treatment By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock - Investing.com India
BMO Capital reaffirms outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
BMO Capital reaffirms outperform rating on Legend Biotech stock - Investing.com India
RBC Capital maintains Legend Biotech at outperform with $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Legend Biotech at outperform with $78 target - Investing.com
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com
Legend Biotech stock holds $62 target, solid Carvykti sales growth - Investing.com India
Legend Biotech stock holds $62 target, solid Carvykti sales growth By Investing.com - Investing.com UK
Truist cuts Legend Biotech stock target to $71, maintains buy rating - Investing.com India
Raymond James maintains Legend Biotech Outperform rating - Investing.com
Raymond James maintains Legend Biotech Outperform rating By Investing.com - Investing.com UK
Earnings call transcript: Legend Biotech Q1 2025 sees strong CARVICTI sales boost - Investing.com India
Legend Biotech Q1 2025 slides: CARVYKTI sales surge 135% as path to profitability clarifies - Investing.com India
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights - GlobeNewswire Inc.
Stock Surge: Legend Biotech Corp ADR (LEGN) Closes at 31.37, Marking a -6.08 Increase/Decrease - DWinneX
What Makes Legend Biotech (LEGN) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):